visualizations
Karsh, Lawrence, MD, FACS, CPI
Overview
overview
- Lawrence I. Karsh, MD, is a Co-Founder of The Urology Center of Colorado, where he serves as an attending urologist and Director of Research & Co-Chairman of the Advanced Therapeutic Clinic. He is a certified principal investigator, and has been the principal investigator on over 250 clinical trials. He has authored a number of peer-reviewed publications and serves on the editorial boards for Oncology Live, Urologists in Cancer Care, and Bladder Cancer. He is a fellow of the American College of Surgeons, and an active member of the AUA, SUO, ASCO, SWOG, ACS, and the Denver Academy of Surgeons. He has served on the bladder cancer subcommittee and the advisory board for the SUO Clinical Trials Consortium and is a member of the Bladder Cancer Advocacy Network (BCAN) Think Tank. Dr. Karsh completed his general surgery training at the University of Colorado Health Sciences Center (UCHSC) and his urology residency at Brigham and Women’s Hospital/Harvard Medical School. He is an Associate Clinical Professor of Surgery at UCHSC. Dr. Karsh participates in many advisory boards for new drug development. He lectures and teaches at scientific meetings throughout the country.
Publications
Most Recent Publications
-
2026Real-world clinical outcomes of patients with localized prostate cancer treated with radical prostatectomy in SEER-Medicare. JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH. 15.Full Text via DOI: 10.57264/cer-2025-0004 PMID: 41693644
-
2026Enzalutamide Monotherapy for the Treatment of Prostate Cancer With High-Risk Biochemical Recurrence: EMBARK Secondary End Points. JOURNAL OF UROLOGY. 215:396-407.Full Text via DOI: 10.1097/ju.0000000000004879
-
2025Secondary outcomes by prior definitive treatment in patients with high-risk biochemically recurrent prostate cancer treated with enzalutamide monotherapy: EMBARK post hoc analysis. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. 119-119.
-
2025Enzalutamide treatment of patients with advanced prostate cancer across the disease spectrum: plain language review. FUTURE ONCOLOGY. 605-616.Full Text via DOI: 10.1080/14796694.2025.2475730 PMID: 40583299
-
2025Abstract LB089: Exploring androgen receptor alterations (ARa) and their potential association with efficacy of first-line (1L) talazoparib (TALA) + enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC): A post hoc analysis of TALAPRO-2. CANCER RESEARCH. 85:LB089-LB089.Full Text via DOI: 10.1158/1538-7445.am2025-lb089
-
2025IP21-27 IsoPSA LARGE SCALE PROSPECTIVE VALIDATION STUDY: PERFORMANCE OF THE IsoPSA TEST IN PATIENTS AGED 50-69 YEARS. JOURNAL OF UROLOGY. 213.Full Text via DOI: 10.1097/01.ju.0001110100.38838.c8.27
-
2025Overall survival in metastatic castration-resistant prostate cancer (mCRPC): A retrospective electronic medical record analysis of men treated with sipuleucel-T in community urology over 14 years.. JOURNAL OF CLINICAL ONCOLOGY. 43.Full Text via DOI: 10.1200/jco.2025.43.16_suppl.e17041
-
2025Patient-Reported Outcomes From Males Regarding Germline Testing for Prostate Cancer: Results From the PROGRESS Registry. JCO Precision Oncology. e2500571.Full Text via DOI: 10.1200/po-25-00571
-
2025Secondary outcomes by prior definitive treatment (tx) in patients (pts) with high-risk biochemically recurrent prostate cancer (hrBCR) treated with enzalutamide (enza) monotherapy (mono): EMBARK post hoc analysis.. JOURNAL OF CLINICAL ONCOLOGY. 43:179-179.Full Text via DOI: 10.1200/jco.2025.43.5_suppl.179
-
2025Secondary outcomes by prior definitive treatment (tx) in patients (pts) with high-risk biochemically recurrent prostate cancer (hrBCR) treated with enzalutamide (enza) monotherapy (mono): EMBARK post hoc analysis.. JOURNAL OF CLINICAL ONCOLOGY. 43:5103-5103.Full Text via DOI: 10.1200/jco.2025.43.16_suppl.5103
-
2024Survival outcomes of apalutamide as a starting treatment: impact in real-world patients with metastatic hormone sensitive prostate cancer (OASIS). PROSTATE CANCER AND PROSTATIC DISEASES. 28:865-873.Full Text via DOI: 10.1038/s41391-024-00929-6 PMID: 39702472
-
2024North American study and meta-analysis evaluating performance of Bladder EpiCheck®, a FDA cleared test, in non-muscle invasive bladder cancer recurrence. BLADDER CANCER. 10:278-289.Full Text via DOI: 10.1177/23523735241304348 PMID: 40035078
-
2024Germline and somatic testing for homologous repair deficiency in patients with prostate cancer (part 1 of 2). PROSTATE CANCER AND PROSTATIC DISEASES. 652-661.Full Text via DOI: 10.1038/s41391-024-00901-4 PMID: 39354185
-
2024Therapeutic implications of homologous repair deficiency testing in patients with prostate cancer (Part 2 of 2). PROSTATE CANCER AND PROSTATIC DISEASES. 601-609.Full Text via DOI: 10.1038/s41391-024-00887-z PMID: 39333696
-
2024Prostate-specific antigen and health-related quality of life in individuals with advanced prostate cancer treated with apalutamide: a plain language summary of the SPARTAN and TITAN studies. FUTURE ONCOLOGY. 2689-2698.Full Text via DOI: 10.1080/14796694.2024.2384257 PMID: 39163505
-
2024Post Hoc Analysis of Rapid and Deep Prostate-specific Antigen Decline and Patient-reported Health-related Quality of Life in SPARTAN and TITAN Patients with Advanced Prostate Cancer. EUROPEAN UROLOGY ONCOLOGY. 7:844-852.Full Text via DOI: 10.1016/j.euo.2023.11.015 PMID: 38072759
-
2024Utility of ctDNA burden as a prognostic biomarker for efficacy in TALAPRO-2: A phase 3 study of talazoparib (TALA) plus enzalutamide (ENZA) vs placebo (PBO) plus ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). JOURNAL OF CLINICAL ONCOLOGY.
-
2024PIVOTAL STUDY EVALUATING PERFORMANCE OF BLADDER EPICHECK, AN FDA CLEARED TEST, IN NON-MUSCLE INVASIVE BLADDER CANCER. JOURNAL OF UROLOGY. E990-E991.
-
2024Differences in real-world outcomes by risk classification for localized prostate cancer patients after radiation therapy. PROSTATE. 84:1047-1055.Full Text via DOI: 10.1002/pros.24720 PMID: 38685667
-
2024Abstract CT018: TMPRSS2-ERG and RB1 as candidate predictive biomarkers for efficacy in TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Cancer Research. 84:CT018-CT018.Full Text via DOI: 10.1158/1538-7445.am2024-ct018
-
2024Development and Optimization of a Subtraction-Normalized Immunocyte Profiling Signature for Prostate Cancer Active Surveillance Risk Stratification. JOURNAL OF UROLOGY. 211:415-425.Full Text via DOI: 10.1097/ju.0000000000003824
-
2024Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guérin–Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial. JOURNAL OF UROLOGY. 212:74-86.Full Text via DOI: 10.1097/ju.0000000000004020
-
2024Survival Outcomes of APA as a Starting treatment: Impact in real-world patients with mCSPC (OASIS).. JOURNAL OF CLINICAL ONCOLOGY. 42:65-65.Full Text via DOI: 10.1200/jco.2024.42.4_suppl.65
-
2023A US real-world study of treatment patterns and outcomes in localized or locally advanced prostate cancer patients. WORLD JOURNAL OF UROLOGY. 41:3535-3542.Full Text via DOI: 10.1007/s00345-023-04680-w PMID: 37966506
-
2023Apalutamide efficacy, safety and wellbeing in older patients with advanced prostate cancer from Phase 3 randomised clinical studies TITAN and SPARTAN. BRITISH JOURNAL OF CANCER. 130:73-81.Full Text via DOI: 10.1038/s41416-023-02492-8 PMID: 37951974
-
2023Use of circulating tumor DNA (ctDNA) to complement tumor tissue homologous recombination repair (HRR) gene alteration testing in TALAPRO-2, a phase 3 study of talazoparib (TALA) plus enzalutamide (ENZA) versus placebo (PBO) plus ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).. JOURNAL OF CLINICAL ONCOLOGY.Full Text via DOI: 10.1200/JCO.2023.41.16_suppl.5056
-
2023Factors related to men's experience with prostate cancer germline testing.. JOURNAL OF CLINICAL ONCOLOGY.
-
2023
-
2023Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials. CLINICAL CANCER RESEARCH. 29:2426-2434.Full Text via DOI: 10.1158/1078-0432.ccr-22-3832
-
2023Outcomes of patients (pts) with de novo metastatic hormone-sensitive prostate cancer (mHSPC) who progressed to metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the TRUMPET registry.. JOURNAL OF CLINICAL ONCOLOGY. 41:e17085-e17085.Full Text via DOI: 10.1200/jco.2023.41.16_suppl.e17085
-
2023Use of circulating tumor DNA (ctDNA) to complement tumor tissue homologous recombination repair (HRR) gene alteration testing in TALAPRO-2, a phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).. JOURNAL OF CLINICAL ONCOLOGY. 41:5056-5056.Full Text via DOI: 10.1200/jco.2023.41.16_suppl.5056
-
2022Impact of darolutamide on local symptoms: pre-planned and post hoc analyses of the ARAMIS trial. BJU INTERNATIONAL. 131:452-460.Full Text via DOI: 10.1111/bju.15887 PMID: 36087070
-
2022Plain language summary of the design of the TALAPRO-2 study comparing talazoparib and enzalutamide versus enzalutamide and placebo in men with metastatic castration-resistant prostate cancer. FUTURE ONCOLOGY. 18:2979-2986.Full Text via DOI: 10.2217/fon-2022-0389 PMID: 35950899
-
2022Efficacy and safety exposure-response relationships of apalutamide in patients with metastatic castration-sensitive prostate cancer: results from the phase 3 TITAN study. CANCER CHEMOTHERAPY AND PHARMACOLOGY. 89:629-641.Full Text via DOI: 10.1007/s00280-022-04427-1 PMID: 35366072
-
2022Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non-muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial. EUROPEAN UROLOGY. 81:223-228.Full Text via DOI: 10.1016/j.eururo.2021.12.009 PMID: 34933753
-
2022Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: TALAPRO-2 Phase III study design. FUTURE ONCOLOGY. 18:425-436.Full Text via DOI: 10.2217/fon-2021-0811 PMID: 35080190
-
2022Concomitant use of oral anticoagulants in patients with advanced prostate cancer receiving apalutamide: A post-hoc analysis of TITAN and SPARTAN studies. AMERICAN JOURNAL OF CANCER RESEARCH. 12:445-+.PMID: 35141028
-
2022Association between patient-reported outcomes (PROs) and changes in prostate-specific antigen (PSA) in patients (pts) with advanced prostate cancer treated with apalutamide (APA) in the SPARTAN and TITAN studies.. JOURNAL OF CLINICAL ONCOLOGY. 40:73-73.Full Text via DOI: 10.1200/jco.2022.40.6_suppl.073
-
2022BXCL701: First-in-class oral activator of systemic innate immunity combined with pembrolizumab, in patients with metastatic castration-resistant prostate cancer (mCRPC) of adenocarcinoma phenotype—Phase 2a results.. JOURNAL OF CLINICAL ONCOLOGY. 40:125-125.Full Text via DOI: 10.1200/jco.2022.40.6_suppl.125
-
2022BXCL701: First-in-class oral activator of systemic innate immunity combined with pembrolizumab, in patients with metastatic castration-resistant prostate cancer (mCRPC) of small-cell neuroendocrine carcinoma (SCNC) phenotype—Phase 2a interim results.. JOURNAL OF CLINICAL ONCOLOGY. 40:126-126.Full Text via DOI: 10.1200/jco.2022.40.6_suppl.126
-
2022Primary Chemoablation of Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer Using UGN-102, a Mitomycin-Containing Reverse Thermal Gel (Optima II): A Phase 2b, Open-Label, Single-Arm Trial. JOURNAL OF UROLOGY. 207:61-69.Full Text via DOI: 10.1097/ju.0000000000002186
-
2022The effect of prior docetaxel (DOC) treatment on efficacy and safety of apalutamide (APA) plus androgen deprivation therapy (ADT) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) from TITAN.. JOURNAL OF CLINICAL ONCOLOGY. 40:89-89.Full Text via DOI: 10.1200/jco.2022.40.6_suppl.089
-
2022VAX014 for instillation in subjects with nonmuscle-invasive bladder cancer.. JOURNAL OF CLINICAL ONCOLOGY. 40:488-488.Full Text via DOI: 10.1200/jco.2022.40.6_suppl.488
-
2021Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial (Oct, 10.1038/s41391-021-00465-7, 2021). PROSTATE CANCER AND PROSTATIC DISEASES. 597-597.Full Text via DOI: 10.1038/s41391-021-00477-3 PMID: 34848822
-
2021Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial. PROSTATE CANCER AND PROSTATIC DISEASES. 25:363-365.Full Text via DOI: 10.1038/s41391-021-00465-7 PMID: 34621011
-
2021
-
2021IMPACT OF DAROLUTAMIDE ON LOCAL SYMPTOMS IN PATIENTS WITH NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER. JOURNAL OF UROLOGY. E586-E587.
-
2021RELATIONSHIPS OF SITES AND BURDEN OF METASTASES WITH LONG-TERM OUTCOMES AND MOLECULAR SUBTYPES IN TITAN. JOURNAL OF UROLOGY. E414-E415.
-
2021Longitudinal follow-up and performance validation of an mRNA-based urine test (Xpert(R) Bladder Cancer Monitor) for surveillance in patients with non-muscle-invasive bladder cancer. BJU INTERNATIONAL. 128:713-721.Full Text via DOI: 10.1111/bju.15418 PMID: 33793062
-
2021Next-generation imaging in localized high-risk prostate cancer. PROSTATE CANCER AND PROSTATIC DISEASES. 585-586.Full Text via DOI: 10.1038/s41391-021-00356-x PMID: 33790419
-
2021BXCL701, first-in-class oral activator of systemic innate immunity pathway, combined with pembrolizumab (Keytruda) in men with metastatic castration-resistant prostate cancer (mCRPC).. JOURNAL OF CLINICAL ONCOLOGY. 39:124-124.Full Text via DOI: 10.1200/jco.2021.39.6_suppl.124
-
2021Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. LANCET ONCOLOGY. 22:107-117.Full Text via DOI: 10.1016/s1470-2045(20)30540-4
-
2021TALAPRO-2: A phase 3 randomized study of enzalutamide (ENZA) plus talazoparib (TALA) versus placebo in patients with new metastatic castration-resistant prostate cancer (mCRPC).. JOURNAL OF CLINICAL ONCOLOGY. 39:TPS5089-TPS5089.Full Text via DOI: 10.1200/jco.2021.39.15_suppl.tps5089
-
2020Variability in adherence to guidelines based management of nonmuscle invasive bladder cancer among Society of Urologic Oncology (SUO) members. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS. 38.Full Text via DOI: 10.1016/j.urolonc.2020.04.026 PMID: 32430255
-
2020Optimizing the management of castration-resistant prostate cancer patients: A practical guide for clinicians. PROSTATE. 1159-1176.Full Text via DOI: 10.1002/pros.24053 PMID: 32779781
-
2020The Oral Gonadotropin-releasing Hormone Receptor Antagonist Relugolix as Neoadjuvant/Adjuvant Androgen Deprivation Therapy to External Beam Radiotherapy in Patients with Localised Intermediate-risk Prostate Cancer: A Randomised, Open-label, Parallel-group Phase 2 Trial. EUROPEAN UROLOGY. 78:184-192.Full Text via DOI: 10.1016/j.eururo.2020.03.001 PMID: 32273183
-
2020Development and evaluation of a bladder Cancer specific survivorship care plan by patients and clinical care providers: a multi-methods approach. BMC HEALTH SERVICES RESEARCH. 20.Full Text via DOI: 10.1186/s12913-020-05533-7 PMID: 32709234
-
2020Clinical Utility of a Genomic Classifier in Men Undergoing Radical Prostatectomy: The PRO-IMPACT Trial. PRACTICAL RADIATION ONCOLOGY. 10:E82-E90.Full Text via DOI: 10.1016/j.prro.2019.09.016 PMID: 31761540
-
2020Androgen Receptor Splice Variant, AR-V7, as a Biomarker of Resistance to Androgen Axis-Targeted Therapies in Advanced Prostate Cancer. CLINICAL GENITOURINARY CANCER. 1-10.Full Text via DOI: 10.1016/j.clgc.2019.09.015 PMID: 31653572
-
2019A 17-gene Panel for Prediction of Adverse Prostate Cancer Pathologic Features: Prospective Clinical Validation and Utility. UROLOGY. 126:76-81.Full Text via DOI: 10.1016/j.urology.2018.11.050 PMID: 30611659
-
2019A Clinician's Guide to Next Generation Imaging in Patients With Advanced Prostate Cancer (RADAR III). JOURNAL OF UROLOGY. 682-692.Full Text via DOI: 10.1016/j.juro.2018.05.164 PMID: 30077557
-
2019
-
2019MULTICENTER CLINICAL TRIAL OF REAL-TIME PROSTATE CANCER DIAGNOSIS USING OPTICAL SPECTROSCOPY GUIDED PROSTATE BIOPSY. JOURNAL OF UROLOGY. E179-E179.
-
2019A phase Ib/II study of niraparib combination therapies for the treatment of metastatic castration-resistant prostate cancer (NCT03431350).. JOURNAL OF CLINICAL ONCOLOGY. 37:TPS5087-TPS5087.Full Text via DOI: 10.1200/jco.2019.37.15_suppl.tps5087
-
2019Antigen (Ag) spread after sipuleucel-T and correlation with overall survival (OS): A real-world experience.. JOURNAL OF CLINICAL ONCOLOGY. 37:e16504-e16504.Full Text via DOI: 10.1200/jco.2019.37.15_suppl.e16504
-
2019Clinical and safety outcomes of TALAPRO-2: A two-part phase III study of talazoparib (TALA) in combination with enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC).. JOURNAL OF CLINICAL ONCOLOGY. 37:5076-5076.Full Text via DOI: 10.1200/jco.2019.37.15_suppl.5076
-
2019TALAPRO-2: A two-part, placebo-controlled phase III study of talazoparib (TALA) with enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC).. JOURNAL OF CLINICAL ONCOLOGY. 37:TPS337-TPS337.Full Text via DOI: 10.1200/jco.2019.37.7_suppl.tps337
-
2019TALAPRO-2: Part 2 (P2) of the placebo-controlled phase 3 study of talazoparib (TALA) with enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC).. JOURNAL OF CLINICAL ONCOLOGY. 37:TPS5092-TPS5092.Full Text via DOI: 10.1200/jco.2019.37.15_suppl.tps5092
-
2018Number-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trials. BMC UROLOGY. 18.Full Text via DOI: 10.1186/s12894-018-0387-7 PMID: 30189902
-
2018Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non-Muscle-Invasive Bladder Cancer on Tumor Recurrence SWOG S0337 Randomized Clinical Trial. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION. 319:1880-1888.Full Text via DOI: 10.1001/jama.2018.4657 PMID: 29801011
-
2018Absorbable Hydrogel Spacer Use in Prostate Radiotherapy: A Comprehensive Review of Phase 3 Clinical Trial Published Data. UROLOGY. 39-44.Full Text via DOI: 10.1016/j.urology.2017.11.016 PMID: 29174940
-
2018DECIPHER TEST IMPACTS ADJUVANT AND SALVAGE TREATMENTS RECEIVED FOLLOWING RADICAL PROSTATECTOMY.. JOURNAL OF UROLOGY. E1148-E1149.
-
2018How I Do It: Hydrogel spacer placement in men scheduled to undergo prostate radiotherapy. CANADIAN JOURNAL OF UROLOGY. 25:9288-9293.PMID: 29680009
-
2018Validating the total illness burden index for prostate cancer (TIBI-CaP) in men with castration-resistant prostate cancer: data from TRUMPET. FUTURE ONCOLOGY. 14:527-536.Full Text via DOI: 10.2217/fon-2017-0438 PMID: 29417827
-
2018Clinical utility of the Prostate Health Index (phi) for biopsy decision management in a large group urology practice setting. PROSTATE CANCER AND PROSTATIC DISEASES. 21:78-84.Full Text via DOI: 10.1038/s41391-017-0008-7
-
2018Comparison of enzalutamide and bicalutamide in patients with non-metastatic castration-resistant prostate cancer: Number needed to treat to achieve one additional patient free of clinical progression events.. JOURNAL OF CLINICAL ONCOLOGY. 36:228-228.Full Text via DOI: 10.1200/jco.2018.36.6_suppl.228
-
2018Impact of decipher test on adjuvant and salvage treatments received following radical prostatectomy.. JOURNAL OF CLINICAL ONCOLOGY. 36:112-112.Full Text via DOI: 10.1200/jco.2018.36.6_suppl.112
-
2018Impact of enzalutamide (ENZA) vs. bicalutamide (BIC) on health-related quality of life (HRQoL) of patients (pts) with castration-resistant prostate cancer (CRPC): STRIVE study.. JOURNAL OF CLINICAL ONCOLOGY. 36:234-234.Full Text via DOI: 10.1200/jco.2018.36.6_suppl.234
-
2018Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017. JOURNAL OF CLINICAL ONCOLOGY. 36:414-424.Full Text via DOI: 10.1200/jco.2017.74.1173
-
2018Talapro-2: A 2-part, placebo-controlled phase 3 study of talazoparib (TALA) with background enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC) with DNA damage repair deficiencies.. JOURNAL OF CLINICAL ONCOLOGY. 36:TPS5091-TPS5091.Full Text via DOI: 10.1200/jco.2018.36.15_suppl.tps5091
-
2017Decipher Test Impacts Decision Making Among Patients Considering Adjuvant and Salvage Treatment After Radical Prostatectomy: Interim Results From the Multicenter Prospective PRO-IMPACT Study. CANCER. 123:2850-2859.Full Text via DOI: 10.1002/cncr.30665 PMID: 28422278
-
2017Continued Benefit to Rectal Separation for Prostate Radiation Therapy: Final Results of a Phase III Trial. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. 97:976-985.Full Text via DOI: 10.1016/j.ijrobp.2016.12.024 PMID: 28209443
-
2017A phase 2 study of TMX-101, intravesical imiquimod, for the treatment of carcinoma in situ bladder cancer. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS. 35.Full Text via DOI: 10.1016/j.urolonc.2016.09.006 PMID: 28341495
-
2017Immune response results from vesigenurtacel-l (HS-410) in combination with BCG from a randomized phase 2 trial in patients with non-muscle invasive bladder cancer (NMIBC).. JOURNAL OF CLINICAL ONCOLOGY. 35:4531-4531.Full Text via DOI: 10.1200/jco.2017.35.15_suppl.4531
-
2017Immune response results of vesigenurtacel-l (HS-410) in combination with BCG from a randomized phase II trial in patients with non-muscle invasive bladder cancer (NMIBC).. JOURNAL OF CLINICAL ONCOLOGY. 35:319-319.Full Text via DOI: 10.1200/jco.2017.35.6_suppl.319
-
2017Intravesical rAd–IFNα/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin–Refractory or Relapsed Non–Muscle-Invasive Bladder Cancer: A Phase II Randomized Study. JOURNAL OF CLINICAL ONCOLOGY. 35:3410-3416.Full Text via DOI: 10.1200/jco.2017.72.3064
-
2017Intravesical rad-IFNα/Syn3 for patients with high-grade, bacillus Calmette-Guérin (BCG) refractory or relapsed non-muscle invasive bladder cancer: A phase II randomized study.. JOURNAL OF CLINICAL ONCOLOGY. 35:279-279.Full Text via DOI: 10.1200/jco.2017.35.6_suppl.279
-
2017MP28-01 A 17-GENE PANEL FOR PREDICTION OF ADVERSE PATHOLOGY AT RADICAL PROSTATECTOMY: PROSPECTIVE VALIDATION. JOURNAL OF UROLOGY. 197.Full Text via DOI: 10.1016/j.juro.2017.02.814
-
2017Rate of occult metastases in patients (pts) with biochemically-recurrent prostate cancer (BRPC) from a phase 2 trial of sipuleucel-T and androgen deprivation therapy (STAND).. JOURNAL OF CLINICAL ONCOLOGY. 35:e16516-e16516.Full Text via DOI: 10.1200/jco.2017.35.15_suppl.e16516
-
2017Reply to M.A.N. Şendur et al and J. Michels. JOURNAL OF CLINICAL ONCOLOGY. 35:123-123.Full Text via DOI: 10.1200/jco.2016.69.9371
-
2017Sequencing of Sipuleucel-T and Androgen Deprivation Therapy in Men with Hormone-Sensitive Biochemically Recurrent Prostate Cancer: A Phase II Randomized Trial. CLINICAL CANCER RESEARCH. 23:2451-2459.Full Text via DOI: 10.1158/1078-0432.ccr-16-1780
-
2016Treatment registry for outcomes in patients with castration-resistant prostate cancer (TRUMPET): a methodology for real-world evidence and research. FUTURE ONCOLOGY. 12:2689-2699.Full Text via DOI: 10.2217/fon-2016-0298 PMID: 27528114
-
2016Safety and efficacy of a patient-controlled bladder management system for treating urinary retention in men. NEUROUROLOGY AND URODYNAMICS. 35:630-635.Full Text via DOI: 10.1002/nau.22770 PMID: 25856157
-
2016Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer. SUPPORTIVE CARE IN CANCER. 24:447-455.Full Text via DOI: 10.1007/s00520-015-2904-5 PMID: 26335402
-
2016Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer (vol 24, pg 447, 2016). SUPPORTIVE CARE IN CANCER. 457-458.Full Text via DOI: 10.1007/s00520-015-2985-1 PMID: 26482379
-
2016Effect of a genomic classifier on adjuvant treatment decision-making among patients with high-risk pathology at radical prostatectomy: Results from the multicenter prospective PRO-IMPACT study.. JOURNAL OF CLINICAL ONCOLOGY. 34:5053-5053.Full Text via DOI: 10.1200/jco.2016.34.15_suppl.5053
-
2016Effect of a genomic classifier on treatment decision-making among patients with biochemical recurrence after radical prostatectomy: Results from the multicenter prospective PRO-IMPACT study.. JOURNAL OF CLINICAL ONCOLOGY. 34:e16558-e16558.Full Text via DOI: 10.1200/jco.2016.34.15_suppl.e16558
-
2016Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial. JOURNAL OF CLINICAL ONCOLOGY. 34:2098-2106.Full Text via DOI: 10.1200/jco.2015.64.9285
-
2016Intramuscular depot formulations of leuprolide acetate suppress testosterone levels below a 20 ng/dL threshold: a retrospective analysis of two Phase III studies. RESEARCH AND REPORTS IN UROLOGY. Volume 8:159-164.Full Text via DOI: 10.2147/rru.s111475
-
2016LB-S&T-21 A PHASE 2 STUDY OF VESIMUNE®, INTRAVESICAL IMIQUIMOD, FOR THE TREATMENT OF CARCINOMA IN SITU BLADDER CANCER. JOURNAL OF UROLOGY. 195.Full Text via DOI: 10.1016/j.juro.2016.03.102
-
2016PD04-02 RENAL FUNCTION BEFORE AND AFTER CYTOREDUCTIVE NEPHRECTOMY IN A PHASE 3 RANDOMIZED CLINICAL TRIAL. JOURNAL OF UROLOGY. 195.Full Text via DOI: 10.1016/j.juro.2016.02.2407
-
2016PD11-07 INTEGRATED RESULTS OF TWO MULTICENTER, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLIND, PHASE 3 TRIALS (SPI-611/612) OF SINGLE-DOSE INTRAVESICAL APAZIQUONE IMMEDIATELY FOLLOWING RESECTION IN PATIENTS WITH NON-MUSCLE INVASIVE BLADDER CANCER. JOURNAL OF UROLOGY. 195.Full Text via DOI: 10.1016/j.juro.2016.02.847
-
2016The TRUMPET registry: Assessing clinical outcomes and quality of life in patients with castration-resistant prostate cancer and their caregivers.. JOURNAL OF CLINICAL ONCOLOGY. 34:241-241.Full Text via DOI: 10.1200/jco.2016.34.3_suppl.241
-
2015A Multi-institutional Prospective Trial in the USA Confirms that the 4Kscore Accurately Identifies Men with High-grade Prostate Cancer. EUROPEAN UROLOGY. 68:464-470.Full Text via DOI: 10.1016/j.eururo.2014.10.021 PMID: 25454615
-
2015Hydrogel Spacer Prospective Multicenter Randomized Controlled Pivotal Trial: Dosimetric and Clinical Effects of Perirectal Spacer Application in Men Undergoing Prostate Image Guided Intensity Modulated Radiation Therapy. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. 92:971-977.Full Text via DOI: 10.1016/j.ijrobp.2015.04.030 PMID: 26054865
-
2015Bone-related Parameters are the Main Prognostic Factors for Overall Survival in Men with Bone Metastases from Castration-resistant Prostate Cancer. EUROPEAN UROLOGY. 68:42-50.Full Text via DOI: 10.1016/j.eururo.2014.10.001 PMID: 25449207
-
2015Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results. JOURNAL FOR IMMUNOTHERAPY OF CANCER. 3.Full Text via DOI: 10.1186/s40425-015-0055-3 PMID: 25901286
-
2015Avoiding obsolescence in advanced prostate cancer management: a guide for urologists. BJU INTERNATIONAL. 188-197.Full Text via DOI: 10.1111/bju.12665 PMID: 25756134
-
2015A Randomized Phase II Trial of Sipuleucel-T with Concurrent versus Sequential Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer. CLINICAL CANCER RESEARCH. 21:3862-3869.Full Text via DOI: 10.1158/1078-0432.ccr-15-0079
-
2015Antigen-specific immune responses through 24 months in the STAND trial: A randomized phase 2 study evaluating optimal sequencing of sipuleucel-T (sip-T) and androgen deprivation therapy (ADT) in biochemically-recurrent prostate cancer (BRPC).. JOURNAL OF CLINICAL ONCOLOGY. 33:171-171.Full Text via DOI: 10.1200/jco.2015.33.7_suppl.171
-
2015Immune responses and clinical outcomes in STAND, a randomized phase 2 study evaluating optimal sequencing of sipuleucel-T (sip-T) and androgen deprivation therapy (ADT) in biochemically-recurrent prostate cancer (BRPC) after local therapy failure.. JOURNAL OF CLINICAL ONCOLOGY. 33:5030-5030.Full Text via DOI: 10.1200/jco.2015.33.15_suppl.5030
-
2014A randomized phase 2 study evaluating optimal sequencing of sipuleucel-T (sip-T) and androgen deprivation therapy (ADT) in biochemically recurrent prostate cancer (BRPC): Preliminary clinical data.. JOURNAL OF CLINICAL ONCOLOGY. 32:5041-5041.Full Text via DOI: 10.1200/jco.2014.32.15_suppl.5041
-
2014Long-term survival in unfavorable-risk mRCC patients treated with a combination of autologous immunotherapy (AGS-003) plus sunitinib.. JOURNAL OF CLINICAL ONCOLOGY. 32:4524-4524.Full Text via DOI: 10.1200/jco.2014.32.15_suppl.4524
-
2014MP70-02 TREATMENT PRACTICE PATTERNS IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS PRIOR TO RECEIVING SIPULEUCEL-T: DATA FROM PROCEED. JOURNAL OF UROLOGY. 191.Full Text via DOI: 10.1016/j.juro.2014.02.2201
-
2013The Transurethral Suprapubic endo-Cystostomy (T-SPeC): A Novel Suprapubic Catheter Insertion Device. JOURNAL OF ENDOUROLOGY. 27:880-885.Full Text via DOI: 10.1089/end.2013.0053 PMID: 23488708
-
2013972 TREATMENT PRACTICE PATTERNS IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) PATIENTS PRIOR TO RECEIVING SIPULEUCEL-T: DATA FROM PROCEED. JOURNAL OF UROLOGY. 189.Full Text via DOI: 10.1016/j.juro.2013.02.553
-
2013A randomized phase II, open-label study of sipuleucel-T with concurrent or sequential abiraterone acetate (AA) in metastatic castrate-resistant prostate cancer (mCRPC).. JOURNAL OF CLINICAL ONCOLOGY. 31:114-114.Full Text via DOI: 10.1200/jco.2013.31.6_suppl.114
-
2013Prolonged survival with personalized immunotherapy (AGS-003) in combination with sunitinib in unfavorable risk metastatic RCC (mRCC).. JOURNAL OF CLINICAL ONCOLOGY. 31:357-357.Full Text via DOI: 10.1200/jco.2013.31.6_suppl.357
-
2012A clinical trial primer: Historical perspective and modern implementation. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS. 30:S28-S32.Full Text via DOI: 10.1016/j.urolonc.2011.05.012 PMID: 22795078
-
2012
-
2011Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. LANCET. 377:813-822.Full Text via DOI: 10.1016/s0140-6736(10)62344-6
Background
Full Name
- Lawrence Karsh, MD
Education
- University of Colorado Health Sciences Center (UCHSC)
Residency
- Brigham and Women’s Hospital/Harvard Medical School
Contact
primary email
- Research.Institute@AdventHealth.com